Shots:
- Merck has reported topline P-II (CADENCE) trial data assessing Winrevair (sotatercept-csrk; 0.3 or 0.7mg/kg) vs PBO in 164 pts with CpcPH due to heart failure with preserved ejection fraction (HFpEF)
- Trial met its 1EP, showing a reduction in pulmonary vascular resistance at 24wks. along with a favorable safety profile. Data will be presented at a future conference & support PoC to guide P-III development of Winrevair
- Winrevair is FDA-approved for adults with PAH (WHO Group 1) to improve exercise capacity, WHO FC, & reduce clinical worsening, hospitalization, lung transplantation, & death
Ref: Merck | Image: Merck | Press Release
Related News:- Merck Reveals P-III (CORALreef HeFH) Trial Data on Enlicitide Decanoate for Heterozygous Familial Hypercholesterolemia (HeFH)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
